Back to today’s briefing

Story perspectives

CRISPR's Casgevy: Hope for 58,000 Sickle Cell Patients

1/17/2025

29 2

Summary

Story summary

CRISPR Therapeutics is making strides with its innovative gene-editing therapy, Casgevy, aimed at combating sickle cell disease and beta-thalassemia. With a robust market cap of $3.45 billion and $1.9 billion in cash, the company seeks to transform the lives of 58,000 patients. Despite facing a 39% stock drop, its promising pipeline in autoimmune diseases presents exciting growth potential.

1 of 1

Story summary

CRISPR Therapeutics is making strides with its innovative gene-editing therapy, Casgevy, aimed at combating sickle cell disease and beta-thalassemia. With a robust market cap of $3.45 billion and $1.9 billion in cash, the company seeks to transform the lives of 58,000 patients. Despite facing a 39% stock drop, its promising pipeline in autoimmune diseases presents exciting growth potential.